Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Breast Carcinoma
|
2793 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1 | 2014 | 2014 | ||||||
Cardiovascular Diseases
|
711 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Factor V Leiden mutation
|
46 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Fetal Growth Retardation
|
21 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Hemophilia A
|
295 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Juvenile Myoclonic Epilepsy
|
46 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1 | 2015 | 2015 | ||||||
Lupus Erythematosus, Systemic
|
1172 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1 | 2011 | 2011 | ||||||
Malignant neoplasm of breast
|
3417 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1 | 2014 | 2014 | ||||||
Malignant Neoplasms
|
1641 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1.000 | 1 | 2020 | 2020 | |||||
Myocardial Infarction
|
680 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Primary malignant neoplasm
|
1374 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1.000 | 1 | 2020 | 2020 | |||||
Protein S Deficiency
|
14 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
Retinopathy of Prematurity
|
16 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Severe hereditary factor VIII deficiency disease
|
15 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Thrombophilia
|
43 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.040 | 1.000 | 4 | 2012 | 2020 | |||||
THROMBOPHILIA DUE TO THROMBIN DEFECT
|
2 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.700 | 1.000 | 14 | 1986 | 2013 | |||||
Inherited Factor II deficiency
|
13 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.700 | 1.000 | 2 | 1998 | 2009 | |||||
Deep Vein Thrombosis
|
93 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.700 | 1.000 | 1 | 2016 | 2016 | |||||
Pulmonary Embolism
|
16 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.700 | 1.000 | 1 | 2016 | 2016 | |||||
Hereditary factor II deficiency disease
|
14 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.700 | 0 | ||||||||
PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 2
|
1 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.700 | 0 | ||||||||
STROKE, ISCHEMIC, SUSCEPTIBILITY TO
|
2 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.700 | 0 | ||||||||
Ischemic stroke
|
704 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.720 | 1.000 | 3 | 2015 | 2016 | |||||
Venous Thromboembolism
|
408 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.730 | 1.000 | 8 | 2012 | 2019 | |||||
Cerebrovascular accident
|
591 | 0.695 | 0.400 | 11 | 46739505 | 3 prime UTR variant | G/A | snv | 9.6E-03 | 0.810 | 1.000 | 6 | 2001 | 2016 |